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Abstract
Background: Fatigue among cancer patients has often been reported in the literature; however, great variations
have been documented, ranging from 15% to 90%, probably due to the lack of a widely accepted definition and
established diagnostic criteria for cancer-related fatigue. The objective of this study was to evaluate the proposed
International Statistical Classification of Diseases and Related Health Problems (10
th revision) (ICD-10) criteria in a
sample of cancer patients from a medical center and a regional teaching hospital in northern Taiwan. More
accurate prevalence estimates of CRF may result in improved diagnoses and management of one of the most
common symptoms associated with cancer and its treatment.
Methods: Since self-reporting from patients is the most effective and efficient method to measure fatigue, the
ICD-10 criteria for fatigue were used. The ICD-10 criteria questionnaire was translated into Chinese and was
approved by experts. Patients were recruited from outpatient palliative and oncology clinics and from palliative
and oncology inpatient units.
Results: Of the 265 cancer patients that were interviewed between 21 October 2008 and 28 October 2009, 228
(86%) reported having at least 2 weeks of fatigue in the past month, and further evaluation with the ICD-10 criteria
showed that 132 (49.8%) had cancer-related fatigue. Internal consistency was very good, which was indicated by a
Cronbach alpha of 0.843.
Conclusion: The prevalence of diagnosable CRF in the patients in this sample, of whom most were under
palliative treatment, was 49.8%, which was probably somewhat lower than in some of the previous reports that
have used less-strict criteria. In addition, among the various criteria of the proposed diagnostic criteria, the most
frequently reported symptoms in our sample populations were regarding sleep disturbance and physical factors.
Although they will require further replication in other samples, these formal diagnostic criteria can serve as a step
toward a common language and a better understanding of the severity range of CRF.
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Background
Fatigue is the most common symptom or complaint
related to cancer and cancer therapy [1], and has been
identified as the most distressful symptom of cancer
patients [2]. Cancer-related fatigue (CRF) profoundly
affects the quality of life (QOL) of both the patients and
their families, physically and psychosocially, as well as in
economic and occupational areas [3].
Cancer-associated fatigue is defined as a subjective
state of overwhelming sustained exhaustion and
decreased capacity for physical and mental work, which
is not relieved by rest [4]. CRF differs from the fatigue
that accompanies everyday life, which is usually tempor-
ary and relieved by rest. In addition to the direct impact
of cancer, various treatment modalities, particularly che-
motherapy and radiation, are known to cause fatigue for
many patients for an extended period of time. Fatigue
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for recognition by the World Health Organization
(WHO) and for publication in the International Statisti-
cal Classification of Diseases and Related Health Pro-
blems (10
th revision) (ICD-10) [5]. Previous studies have
varied in their reports of the prevalence of fatigue in
cancer patients. Although not based on formal diagnos-
tic criteria, between 58% and 90% of patients receiving
cancer therapy have reported experiencing fatigue [6,7].
The reported prevalence of fatigue in patients with
advanced cancer has ranged from 51% to 89% [8,9].
Typically, a cancer patient need only say that he or she
is experiencing fatigue to be considered to have CRF.
Therefore, existing prevalence estimates may be high
and non-discriminating. Current prevalence estimates
may combine both patients with everyday fatigue and
those who have more clinically significant, definable
CRF.
The assessment of fatigue is multidimensional in nat-
ure [10]. Ambiguity in the literature and a previous lack
of specific tools to measure fatigue created difficulties in
establishing assessment and management guidelines.
Most practitioners would agree that a working set of
diagnostic criteria is essential for research and treatment
planning. To end that, the Fatigue Coalition, a multidis-
ciplinary group of medical practitioners, researchers,
and patient advocates, proposed a set of diagnostic cri-
teria in 1998 (Table 1). To date, there are no prevalence
data in Taiwan using the proposed ICD-10 criteria. The
purpose of this study was to examine the prevalence
and functional impact of CRF in a sample of Taiwanese
cancer patients.
Methods
Participants and Settings
Data about cancer patients suspected to be fatigued
were recruited from outpatient oncology and palliative
clinics and oncology and palliative inpatient units at a
medical center and a district teaching hospital in north-
ern Taiwan. Selection criteria required that patients
have a pathological diagnosis of cancer, be at least 18
years old, and be able to communicate in Mandarin or
Taiwanese. Patients were excluded if they were cogni-
tively impaired, if they refused to participate, or if they
could not understand the intent of this study. A final
sample of 265 patients was recruited for this study. Fati-
gue was assessed using the proposed ICD-10 criteria for
cancer-related fatigue. Other data collected included
demographics (sex, age), educational level, history of dis-
ease (type of tumor), staging of disease, and current
treatment (e.g., curative treatment, palliative treatment,
chemotherapy, radiotherapy, etc.). Written consent was
given before the assessment of CRF.
This study was reviewed and approved by the Institu-
tional Review Board of Mackay Memorial Hospital and
Cardinal Tien Hospital.
Instruments
The International Classification of Diseases recently
included diagnostic nomenclature for CRF. These cri-
teria have been proposed as a draft of a structured inter-
v i e wg u i d et oh e l pe n s u r et h ed i a g n o s i so fC R F ,a n d
were made in a standardized way across research and
clinical applications by Dr. Cella [11]. In 2005, several
researchers validated the use of the proposed ICD-10
Table 1 Proposed (1998 draft) ICD-10 Criteria for Cancer-Related Fatigue
Six (or more) of the following symptoms have been present every day or nearly every day during the same 2-week period in the past
month, and at least one of the symptoms is (A1) significant fatigue.
A1. Significant fatigue, diminished energy, or increased need to
rest, disproportionate to any recent change in activity level
A2. Complaints of generalized weakness or limb heaviness
A3. Diminished concentration or attention
A4. Decreased motivation or interest to engage in usual activities
A5. Insomnia or hypersomnia
A6. Experience of sleep as unrefreshing or nonrestorative
A7. Perceived need to struggle to overcome inactivity
A8. Marked emotional reactivity (eg, sadness, frustration,
or irritability) to feeling fatigued
A9. Difficulty completing daily tasks attributed to feeling fatigued
A10. Perceived problems with short-term memory
A11. Postexertional malaise lasting several hours
B. The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning
C. There is evidence from the history, physical examination, or laboratory
findings that the symptoms are a consequence of cancer or cancer therapy.
D. The symptoms are not primarily a consequence of comorbid psychiatric
disorders such as major depression, somatization disorder, somatoform disorder, or delirium.
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scales, namely the FACT-F and VAS, and discovered
that the internal consistency of P-ICD 10 criteria was
very good, with an alpha coefficient of 0.82, and con-
cluded that the ICD-10 criteria can be recommended as
a diagnostic tool for cancer-related fatigue [12]. We
were authorized by Dr. Cella to use the diagnostic inter-
view guide for CRF, and its Chinese-language version,
for application in a clinical and research setting to
determine the prevalence of CRF in Taiwan.
The English version of the diagnostic interview guide
questionnaire was initially translated into Chinese by
one of the professional translator, who is bilingual in
Chinese and English and experienced in the study topic.
A second qualified and blinded bilingual expert back-
translated the Chinese version of the diagnostic inter-
view guide questionnaire, creating a new English ver-
sion. A monolingual reviewer on the research team then
compared the original and back translated versions of
the diagnostic interview guide questionnaire. The initial
question inquired whether the patient had experienced
significant fatigue, a lack of energy, or an increased need
to rest for a least a 2-week period during the last
month. Given the many causes of fatigue and its multi-
dimensional manifestations, the next 10 questions
included 10 common clinical manifestations of fatigue
reported by cancer patients. The last 3 questions were
arranged to exclude non-CRF (Table 2).
Prior to the data collection for the current study, the
coordinator of this study (Y.L.) met the interviewers of
this study (E.Y, Y.T., and W.S.) for training purposes.
The training involved a review of the diagnostic criteria,
the completion of simulated interviews, and the comple-
tion of actual interviews conducted with patients who
were not participants of this study. The interviews of
this study were conducted by 2 physicians and 1 nurse
Table 2 Diagnostic interview guide for cancer-related fatigue
Diagnostic Interview Guide for Cancer-Related Fatigue
NOTE: Capitalized text represents instructions to the interviewer. Text in quotations represents statements to be read verbatim to
respondent.
1 “Over the past month, has there been at least a 2-week period when you had significant fatigue, a lack of
energy, or an increased need to rest every day or nearly every day?”
CIRCLE ONE: YES NO
IF NO, STOP HERE. IF YES, CONTINUE
“For each of the following questions, focus on the worst 2 weeks in the past month (or else tha past 2 weeks if you felt equally fatigued for the
entire month).”
2. “Did you feel weak all over or heavy all over? (every day or nearly every day?)” CIRCLE ONE: YES NO
3. “Did you have trouble concentrating or paying attention? (every day or nearly every day?)” CIRCLE ONE: YES NO
4. “What about losting your interest or desire to the things you usually do? (every day or nearly every day?)” CIRCLE ONE: YES NO
5. “How were you sleeping? Did you have trouble falling asleep, staying asleep, or waking too early? Or did
you find yourself sleeping too much compared to what you usually sleep? (every day or nearly every day?)”
CIRCLE ONE: YES NO
6. “Have you found that you usually don’t feel rested or refreshed after you have slept? (every day or nearly
every day?)”
CIRCLE ONE: YES NO
7. “Did you have struggle or push yourself to do anything? (every day or nearly every day?)” CIRCLE ONE: YES NO
8. “Did you find yourself feeling sad, frustrated, or irritable because you felt fatigued? (every day or nearly
every day?)”
CIRCLE ONE: YES NO
9. “Did you have difficulty finishing something you had started to do because of feeling fatigued? (every day
or nearly every day?)”
CIRCLE ONE: YES NO
10. “Did you have trouble remembering things? For example, did you have trouble remembering where your
keys were or what someone had told you a little while ago? (every day or nearly every day?)”
CIRCLE ONE: YES NO
11. “Did you find yourself feeling sick or unwell for several hours after you had done something that took
some effort(every time or nearly every time?)”
CIRCLE ONE: YES NO
IF LESS THAN SIX ITEMS INCLUDING #1 ARE MARKED YES, STOP HERE.
12. “Has fatigue made it hard for you to do your work, take care of things at home, or get along with other
people?”
CIRCLE ONE: YES NO
IF #12 IS NO, STOP HERE
13. IS THERE EVIDENCE FROM THE HISTORY, PHYSICAL
EXAMINATION, OR LABORATORY FINDINGS THAT THE SYMPTOMS ARE A CONSEQUENCE OF CANCER OR
CANCER TREATMENT?
CIRCLE ONE: YES NO
IF #13 IS NO, STOP HERE
14. ARE THE SYMPTOMS PRIMARILY A CONSEQUENCE OF CO-MORBID PSYCHIATRIC DISORDERS SUCH AS
MAJOR DEPRESSION, SOMATIZATION DISORDER, SOMATOFORM DISORDER, OR DELIRIUM?
CIRCLE ONE: YES NO
IF #14 IS YES, PATIENT DOES NOT MEET CRITERIA FOR CANCER-RELATED FATIGUE
IF #14 IS NO, PATIENT MEETS CRITERIA FOR CANCER-RELATED FATIGUE
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all experienced in working with cancer patients. Sixteen
interviews were tape-recorded for the purpose of deter-
mining inter-rater reliability. Ratings obtained from the
interviewers were compared with those from the inde-
pendent rater (S.L.) who was trained for the administra-
tion of the interviews but not involved in the data
collection of this study. The level of the overall agree-
ment between the study interviewers and the indepen-
dent rater regarding the presence/absence of cancer-
related fatigue was 95%. After calculation, we obtained
that the coefficient of kappa, a measurement adjusted
for base rates, was 0.88. The level of the overall agree-
ment between the study interviewers and the indepen-
dent rater regarding the presence/absence of the 14
individual criteria that comprise the diagnostic interview
g u i d ef o rC a n c e r - R e l a t e dF a t i g u e( k a p p a=0 . 9 6 )w a s
90%. According to the rule of thumb, values of Kappa
from 0.40 to 0.59 are considered moderate, 0.60 to 0.79
substantial, and 0.80 outstanding (Landis & Kochi,
1977). Most statisticians prefer Kappa values to be at
least 0.6 and most often higher than 0.7 before claiming
a good level of agreement.
A pretest was performed in which 21 Chinese-lan-
guage versions of the diagnostic interview guide were
completed before the study. Descriptive statistics were
computed per patient group as P-ICD-positive or P-
ICD-negative. Internal consistency of the P-ICD-10 was
assessed by computing Cronbach’s alpha coefficient. The
correlations of each question were examined, and the
values of the alpha coefficient showed medium strength
correlations (ranging from 0.11 to 0.3). These indicated
the instrument is a reliable tool for measuring fatigue.
Results
Participant Characteristics
Demographic and disease-related characteristics of the
patients are presented in Table 3. Data on the 265
patients, of whom 64% were women, were collected
between 21 October 2008 and 28 October 2009 at two
Taipei clinical centers (Mackay Memorial Hospital, n =
200, Cardinal Tien Hospital, n = 65). Of the 265
patients, 228 (86%) answered “yes” to the first question
of the questionnaire, which corresponds to criterion A1
of the P-ICD criteria of CRF, and requires a person to
report a minimum of 2 weeks of fatigue in the past
month. Criterion A specifies that six or more symptoms
must have been resent every day or nearly every day
during the same 2-week period of time over the past
month and at least one symptom must be significant
fatigue. Table 4 lists individually by symptom, the num-
ber and the percentages from criteria A1 to A11, which
corresponds to questions number 1 to 11, respectively.
Criterion B specifies that the fatigue symptoms must
cause clinically significant distress or impairment in
social, occupational, or other important areas of func-
tioning. Thirty patients (11%) had six or more of the
symptoms in criterion A but responded that the symp-
toms did not cause significant distress or impairment in
social, occupational, or other important areas of func-
tioning (Table 5). The part in Table 4 in bold fonts (A1
+ any 5 + B) shows that criteria A and B of the P-ICD-
10 diagnostic criteria were met by 28 (11%) patients.
This result is compared with a western study of 375
patients conducted by Cella D, Davis K, Breitbart W, et
al. showing that 17% of patient respondents met both
Criteria A and B [11]. In addition, of the 265 patients,
132 (49.8%) were classified as fatigue-positive according
to the P-ICD-10. 66 subjects were more than 70 years
old (24.9%), 61 subjects were between 61 to 70 years old
(23%), 81 subjects were between 51 to 60 years old
(30.5%), 37 subjects were between 41 to 50 years old
(13.9%), 14 subjects were between 31 to 40 years old
(5.2%), and 3 subjects were below 30 years old (1/1%).
15% of the patients did not receive education, and 22%
had some college or higher education. The different age
groups and education levels were not statistically signifi-
cant if they were classified as P-ICD 10-positive and P-
ICD 10-negative. The participants were diagnosed with
various types of cancer, including head and neck (7.9%),
lung and mediastinum (10.5%), breast (36.6%), liver
(3.7%), GI tract (16.6%), GU tract (3.3%), GYN (6.4%),
prostate (3.3%), hematological malignancy (0.3%), and
others (8.6%). Notably, the breast (p = 0.033) and GI
tract (0.035) were statistically significant if they were
classified as P-ICD 10-positie and P-ICD 10-negative (p
< 0.05). Among the 132 patients who were classified as
fatigue-positive according to the P-ICD-10, 77 patients
are under palliative treatment, 18 patients received cura-
tive treatment, and 35 patientswere follow up after cura-
tive therapy. The group under palliative treatment and
curative treatment were statistically significant if they
were classified as P-ICD 10-positive and P-ICD 10-nega-
tive (p < 0.05). In addition, regarding the staging of the
disease, the group under no signs and symptoms and
tumor progression were statistically significant if they
were classified as P-ICD 10-positive and P-ICD 10-nega-
tive (p < 0.005).
Internal consistency of the P-ICD-10
Occurrences of each P-ICD-10 fatigue symptom in all
patients, and patients classified as P-ICD 10-positive (N
= 129) and P-ICD 10-negative (N = 380) are listed in
Table 6.
According to the design of the questionnaire, the 1
st
question, which corresponds to the A1 criteria of the P-
ICD-10 criteria, should be answered “yes” in order for
the questionnaire to proceed, thereby resulting in the
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the 10 other complaints, the most frequently reported
by both P-ICD 10-positive and P-ICD 10-negative
patients were “general weakness”, “insomnia or hyper-
somnia”, “experience of sleep as unrefreshing or non-
restorative”,a n d“perceived problems with short-term
memory”. The most discriminative complaints were
related to physical fatigue, and they are listed according
to the order of their discriminative properties: “Difficulty
completing daily tasks attributed to feeling fatigued” (P-
ICD 10-positive 76%, negative 19.9%), “Perceived need
to struggle to overcome inactivity” (P-ICD 10-positive
70.5%, negative 16.2%), and “Post-exertional malaise
lasting several hours” (P-ICD 10-positive 72.9%, negative
Table 3 Sample Characteristics
P-ICD 10-positive
(N = 132)
No. (%)
P-ICD 10-negative
(N = 133)
No. (%)
P-value
Sex
Male 49 (37) 44 (33)
Female 83 (63) 89 (67)
Age
> 70 36 (27) 30 (23)
61-70 33 (25) 28 (21)
51-60 37 (28) 44 (33)
41-50 16 (12) 21 (16)
31-40 8 (6) 6 (5)
< 30 1 (1) 2 (2)
Education
Did not receive education 24 (18) 16 (12)
Elementary 42 (32) 43 (32)
high school 36 (27) 38 (29)
College 25 (19) 29 (22)
College graduate 1 (1) 4 (3)
Missing 4 3
Cancer diagnosis
Head & Neck 9 12
Lung & Mediastinum 12 16
Breast 39 58 0.033*
Liver 5 5
GI tract(except liver) 29 15 0.035*
GU tract 6 3
GYN 8 9
Prostate 7 2
Hematological malignancy 2 0
Others 10 13
Missing 2 3
Treatment Modalities
Palliative treatment 77 51 0.022*
Curative treatment 18 38 0.088*
F/U after curative treatment 35 43
Condition of the Disease 23 0
No signs and symptoms 30 51 0.02*
Stationary state 13 20
Progression (local invasion) 35 18 0.02*
Progression (Metastasis) 28 15 0.047*
Terminal stage 27 21
Missing 5 2
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about sleep quality, which is the 5
th question on the
questionnaire: “insomnia or hypersonmia”.
Internal consistency was established by calculating
Cronbach alpha coefficients, which were 0.843, indicat-
ing good internal consistency for the Chinese-language
version of the P-ICD 10 criteria. Removing non-reliable
items would increase internal consistency. The alpha
coefficient did not increase after removing any indivi-
dual item, removing any item decreased the internal
consistency, and the most reliable items, aside from the
1
st symptom, were the 7
th,9
th,a n d2
nd symptom,
respectively.
Content Validity
To guarantee cultural equivalence and to establish
expert validity, 7 authoritative specialists in the field of
nursing, oncology, radio-oncology, psychiatry, and lin-
guistics were formed to examine the Chinese-language
version of the P-ICD 10 criteria. The experts were asked
to rate the relevance of the content independently using
a content validity index (CVI). They were asked to rate
each item on the Chinese-language versions of the diag-
nostic interview guide based on relevance and semantic
equivalence using the following 4-point Likert scale: 1 =
not relevant (not appropriate), 2 = somewhat relevant
(somewhat appropriate), 3 = relevant (quite appropriate),
4 = very relevant (very appropriate). The CVI was then
computed based on the percentage of total items rated
by the experts as either 3 or 4. According the Norwood
(2000), a CVI rating exceeding .80 can be considered to
show good content validity. All items in the Chinese-
language versions of the diagnostic interview guide were
rated by the panel experts as having a CVI greater than
. 9 0 .F o rt h ef i n a lv e r s i o n ,t h eC V I sf o rr e l e v a n c ea n d
semantic equivalence both reached .99.
Discussion
Fatigue is an important and one of the most prevalent
complaints of cancer patients both during and after
treatment [13], and previous reports demonstrated that
the prevalence of cancer fatigue is up to 90% [14]. In
this study, 86% of patients reported significant fatigue,
which is the first question of the questionnaire, indicat-
i n gt h a ti ti sav e r yc o m m o ns y m p t o mf o rT a i w a n e s e
cancer patients. This result is consistent with other stu-
dies. The prevalence of CRF was studied in 2 national
surveys conducted by Fatigue Coalitions, which studied
419 and 197 cancer patients, and showed an overall 74%
of patients reporting fatigue [15]. Another large-scale
survey of 379 cancer patients who had received che-
motherapy with or without radiation therapy showed
fatigue was present in 75% of patients, with patients
reporting fatigue as the symptom that most affected
QOL, followed by nausea, depression, and pain [16]. In
another study, 58% of a sample of cancer patients
receiving cancer therapy reported that fatigue had
Table 4 Patients who endorsed category A criteria
(N = 265)
Criterias N %
A1 Two weeks of fatigue in past month 228 86%
A2 General weakness 172 65%
A3 Trouble concentrating 133 50%
A4 Decreased motivation 115 43%
A5 Insomnia/hypersomnia 162 61%
A6 Nonrestorative sleep 175 66%
A7 Having to push things 113 43%
A8 Sadness or frustration 106 40%
A9 Trouble completing daily tasks 125 47%
A10 Short-term memory problems 162 61%
A11 Postexertional malaise 123 46%
Table 5 Patients who endorsed multiple symptoms
(Criteria A) and Criteria B (N = 265)
Multiple Symptoms Reports N %
Did not responded to A1 37 14%
Only responded A2 4 2%
A1 + any 1 7 3%
A1 + any 2 12 5%
A1 + any 3 26 10%
A1 + any 4 20 8%
A1 + any 5 + B* 28 11%
A1 + any 6 + B 14 5%
A1 + any 7 + B 21 8%
A1 + any 8 + B 23 8%
A1 + any 9 + B 22 8%
A1 + any 10 + B 24 9%
A1 + any 5 or more but does not responded to B 30 11%
Table 6 Occurrences of each P-ICD 10 symptoms
classified as positive and negative
P-ICD 10
positive
N (%)
P-ICD 10
negative
N (%)
A2 General weakness 113 (87.6%) 59(43.4%)
A3 Trouble concentrating 87(67.4%) 46(33.8%)
A4 Decreased motivation 85(65.9%) 30(22.1%)
A5 Insomnia/hypersomnia 101(78.3%) 61(44.9%)
A6 Nonrestorative sleep 114(88.4%) 61(44.9%)
A7 Having to push things 91(70.5%) 22(16.2%)
A8 Sadness or frustration 81(62.8%) 25(18.4%)
A9 Trouble completing daily tasks 98(76.0%) 27(19.9%)
A10 Short-term memory problems 105(81.4%) 57(42.0%
A11 Post-exertional malaise 94(72.9%) 29(21.3%)
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affected them significantly more than any other cancer
symptom [6]. In addition, another study reported that
up to 75% of advanced-cancer patients suffered from
significant fatigue [17]. These results indicated that fati-
gue is a prevalent symptom related to cancer and cancer
therapy. However, cancer fatigue is often underestimated
as the oncologist’s attention is focused primarily on
tumor-related parameters sucha sd i s e a s e - f r e es u r v i v a l
or on treatable symptoms such as pain [18]. This situa-
tion is explained by a lack of communication between
physician and patient regarding fatigue [15]. The lack of
interest in fatigue as a topic for research has also been
attributed to the lack of any effective treatment strategy
[19]. A survey of 470 health care personnel from various
clinical areas demonstrated their poor knowledge and
practice regarding fatigue assessment and management
[20].
Another reason for the lack of interest in research on
CRF is the lack of validated and clinically easy-to-use
assessment tools [13]. Similar to pain, fatigue is com-
monly conceptualized as a multidimensional sensation
that incorporates sensory, cognitive, affective, behavioral,
and physiologic components [21]. However, unlike pain,
no universally accepted definition or well-conceptualized
dimensions for fatigue have been proposed [22].
Although a multidimensional measurement may seem
appropriate, and there are currently numerous multidi-
mensional scales available, those scales may be too long
for fatigued patients to complete and are therefore not
suitable for clinical use. Moreover, unidimensional scales
such as the BFI may not capture the multiple dimen-
s i o n so ff a t i g u ea n dt h e r e f o r ea r em o r es u i t a b l ef o r
screening or measuring the intensity of fatigue. This pic-
ture supports the need for reliable instruments to diag-
nose and assess cancer-related fatigue. Since the P-ICD-
10 criteria have good internal consistency and can be
recommended as a diagnostic tool [12], they were used
with 265 patients in 2 clinical centers in Taiwan. The P-
ICD-10 is structured as a multidimensional instrument
and the present results confirm its good internal consis-
tency with an alpha coefficient of 0.843 with all indivi-
dual items being reliable. “Insomnia or hypersomnia”,
showed the lowest correlation with the other items,
though it is also one of the most frequently reported
symptoms of both ICD-10-positive and ICD-10-negative
symptoms.
Although 86% of our patients reported fatigue, further
investigation using the P-ICD-10 criteria demonstrated a
significantly lower percentage (48.6%), as compared with
currently reported estimates of CRF, which range from
60% to 90%. However, unlike all other previous studies
that provide the percentage of individuals who reported
any degree of fatigue, regardless of its impact on
functioning, this study required that there be significant
fatigue-related problems and disruption in daily func-
tioning to assign the diagnosis. Thus, we distinguished
between fatigue as a symptom reported by the vast
majority of people with cancer, and CRF as a diagnostic
entity.
The most frequently reported symptom of our sample
population, whether the patients were classified as hav-
ing CRF or not, was that of the 6
th question in the ques-
tionnaire, which corresponds to criteria A6 of the P-
ICD-10, “experience of sleep as unrefreshing or non-
restorative”, and it was also the symptom most fre-
q u e n t l yr e p o r t e db yb o t ht h eP - I C D1 0p o s i t i v ea n d
negative patients. Sleep disturbance associated with fati-
gue is often difficult to treat and manage. It may be
influenced by numerous factors, including daytime naps,
depression, anxiety, certain medications, tumor pain,
sleep disruption on account of increased urination or
hot flushes, and evening food and beverage intake.
Although sleep disturbance is common in patients with
cancer, it has been evaluated in few studies. In a pilot
study of women receiving adjuvant chemotherapy for
breast cancer, stimulus control (i.e., having a consistent
time to lie down and get up, avoiding caffeine and sti-
mulating activity in the evening) and sleep restriction (i.
e., avoiding long or late afternoon naps, limiting time in
bed to the normal hours of sleep only) significantly
improved fatigue [23]. The benefit of a multimodality
sleep hygiene program was suggested in a controlled
study of 2 different interventions (relaxation techniques
or autogenic training) for up to 6 months; compared
with the control group, both intervention groups had
significantly better sleep latency, sleep duration, and
daytime functioning [24]. In addition, cognitive-beha-
vioral therapy and stress reduction also may help insom-
nia and sleep disorder [25].
The 2
nd most frequently reported symptom among
our sample patients, whether they were diagnosed as
having CRF or not, was that of the 2
nd question on the
questionnaire, “complaints of generalized weakness or
limb heaviness”. With an incidence of 65%, which was
related to physical fatigue, it was also the 2
nd most fre-
quently reported symptom by both the P-ICD-10-posi-
tive and negative patients. In addition, the most
discriminating complaints were also related to physical
fatigue, such as “difficulty completing daily tasks attribu-
ted to feeling fatigue”, “perceived need to struggle to
overcome inactivity”,a n d“post-exertional malaise last-
ing several hours”. This indicated that physical issues
are important factors in fatigue among cancer patients,
and the incidence is even higher for patients who met
the P-ICD-10 criteria. Quite a number of previous stu-
dies identified a decrease in activity level and muscle
power related to cancer patients [26]. A consistent
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lead to a reduced tolerance for normal activity and
result in high levels of fatigue. The specific mechanism
causing such a phenomenon remains essentially
unknown. Current theory links cancer asthenia with a
similar mechanism purported to play a role in produ-
cing the anorexia-cachexia syndrome, and the profound
fatigue and fever associated with some infectious dis-
eases. An immune response to the tumor resulting in
activation of macrophages and the release of cytokines,
such as tumor necrosis factor, IL-1, IL-6, and inter-
feron-r, is central to the current model, as is the release
of tumor by-products [27,28]. Exercise has been shown
to have the strongest evidence of benefit [29]. A struc-
tured aerobic exercise program has been shown in sev-
eral trials to reduce fatigue and emotional distress and
to improve quality of life in cancer patients who exer-
cised during treatment. Exercise regimens usually
included walking or cycling [30-32]. According to
NCCN guidelines for the management of CRF, exercise
is the intervention with the most supporting evidence
for effectiveness (category 1).
Fatigue is a multidimensional symptom. It may lead to
influences on physical, psychological, spiritual and the
social field. However, even now, the cause of fatigue
cannot be readily identified, and it is difficult to properly
diagnose the symptom. Thus there is no specific treat-
ment for fatigue. And possible influential factors cannot
be removed to ease the symptom and show curative
effect. We could only reduce the symptom and provide
the psychosocial and spiritual support for those with
CRF. For the patients with fatigue, we recruit them for
the holistic approach of palliative care which includes
psychosocial and spiritual approach and psycho-oncol-
ogy consultation. As for those with progressive fatigue,
trials with Steroids and Ritalin were applied with some
subjective response. The symptom management also
includes non-pharmacological intervention, such as
exercise, stress reduction, counseling, and psychosocial
support. Complementary and alternative medicine such
as Chinese Medicine might play some roles in fatigue
management and should be studied in the future. The
development of guidelines for managing fatigue in can-
cer patients depends on continued progress in under-
standing its pathophysiology and many contributing
factors, and we believe the treatment of fatigue will be
optimized by proper diagnosis, and a comprehensive
strategy will probably produce the best results given the
many causes of fatigue and its multidimensional
manifestation.
The results of this study should be interpreted with
caution because of certain limitations. There is a possibi-
lity that the sample of patients studied is not representa-
tive of the general population of Taiwan cancer patients,
since the patients recruited were from northern Taiwan.
Moreover, patients with cognitive impairment and poor
communication skills were excluded, and this may result
in underestimation of the prevalence of fatigue.
Conclusion
In conclusion, the P-ICD-10 criteria for CRF have good
internal consistency, and are a reliable and clinically
easy-to-use measurement of fatigue in Taiwanese cancer
patients. In addition, our results showed a high inci-
dence of fatigue among our sample of cancer patients,
mostly due to sleep disturbances and physical factors.
Further investigation of the management of fatigue,
including pharmaceutical, psychological or physical
treatment, is greatly needed. It is our hope that the
refining and use of these diagnostic criteria will help
better support CRF research and clinical management,
and improve communication between patients and
clinicians.
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